Novimmune
Swiss pharmaceutical company
From Wikipedia, the free encyclopedia
Novimmune is a privately held Swiss pharmaceutical development company focusing on monoclonal antibody therapies for treatment of immune-related diseases.[1] The company was founded in 1998.[2]
Novimmune has six publicly disclosed drug in their pipeline:
- NI-0101, an anti-TLR4 antibody being developed in partnership with Genentech. A phase I clinical trial was completed in 2014[3] and phase II trials are expected to begin in early 2017.[4]
- NI-0401, an anti-CD3ε antibody being developed in partnership with Tiziana Life Sciences. Phase II trials in patients with Crohn's disease and transplant rejection finished in 2008 and 2009, respectively.[5]
- NI-0501, an anti-IFNγ antibody, is in development for hemophagocytic lymphohistiocytosis.[6][7] A phase II/III trial began in 2013 and is ongoing.[8] The FDA awarded breakthrough status to the drug in 2016.[9]
- NI-1401, an anti-IL17 drug being developed in partnership with Genentech for inflammatory and auto-immune diseases.[10]
- NI-1701, an anti-CD47, anti-CD19 bispecific antibody in development for treatment of B-cell hematological cancers.
- NI-1801, an anti-CD47, anti-mesothelin bispecific antibody in the preclinical phase of development for treatment of solid tumors.[11]
No drugs have been approved yet.